GlassScriptPhysician profile
Antonio J Decarli
NPI 1376644328
$6,425.66
in general payments reported to CMS, 2019-2025
33 companies · $2,479 in 2025
The $2,479 reported for 2025 was more than what 83% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $435 · 2021: $621 · 2022: $870 · 2023: $220 · 2024: $1,543 · 2025: $2,479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,722 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,499 · Education: $20.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,722.44 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,498.95 |
| Education | $20.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,371.05 | 2019-2025 | Rinvoq, Linzess, Creon |
| Janssen Biotech, INC. | $413.43 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $339.19 | 2019-2025 | Entyvio, Eohilia |
| Celltrion USA INC. | $279.21 | 2024-2025 | Vegzelma, Zymfentra |
| Ipsen Biopharmaceuticals, INC | $258.73 | 2025 | Iqirvo |
| Braintree Laboratories, INC. | $220.00 | 2019-2025 | Suflave |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $217.12 | 2019-2024 | Trulance |
| Ferring Pharmaceuticals INC. | $174.08 | 2020-2025 | Rebyota |
| Merck Sharp & Dohme LLC | $116.35 | 2020-2024 | Dificid |
| Evoke Pharma, INC. | $112.86 | 2020-2022 | |
| Allergan, INC. | $112.35 | 2019-2022 | |
| Intercept Pharmaceuticals, INC. | $96.48 | 2020-2024 | |
| Aimmune Therapeutics, INC. | $60.97 | 2025 | Zenpep |
| Gilead Sciences, INC. | $60.83 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $59.32 | 2024 | Voquezna |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $57.20 | 2022-2025 | |
| Nestle Healthcare Nutrition INC. | $49.68 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $47.83 | 2021-2024 | |
| Vivus LLC | $47.59 | 2021-2022 | |
| Madrigal Pharmaceuticals | $46.41 | 2025 | Rezdiffra |
| Novo Nordisk INC | $45.06 | 2025 | Wegovy |
| Medtronic, INC. | $40.69 | 2022-2025 | Interstim |
| Axonics, INC. | $30.64 | 2023-2024 | Axonics |
| Ardelyx, INC. | $25.31 | 2024 | Ibsrela |
| Enterra Medical, INC. | $24.30 | 2023 | |
| Pfizer INC. | $24.15 | 2025 | |
| Pharmacosmos Therapeutics INC. | $21.55 | 2021 | |
| Teleflex LLC | $20.02 | 2025 | Urolift |
| Qol Medical, LLC | $16.78 | 2021 | |
| Daiichi Sankyo INC. | $16.28 | 2022 | |
| Phadia US INC. | $16.28 | 2021 | |
| Romark Laboratories, Lc | $3.92 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonio Decarli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.